Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Enterprise Value (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Enterprise Value for 12 consecutive years, with -$170.2 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 92.63% to -$170.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$170.2 million through Dec 2025, down 92.63% year-over-year, with the annual reading at -$170.2 million for FY2025, 92.63% down from the prior year.
  • Enterprise Value for Q4 2025 was -$170.2 million at Theravance Biopharma, up from -$177.2 million in the prior quarter.
  • The five-year high for Enterprise Value was -$88.4 million in Q4 2024, with the low at -$486.8 million in Q3 2022.
  • Average Enterprise Value over 5 years is -$189.9 million, with a median of -$168.8 million recorded in 2023.
  • The sharpest move saw Enterprise Value soared 72.47% in 2023, then tumbled 252.63% in 2025.
  • Over 5 years, Enterprise Value stood at -$173.5 million in 2021, then plummeted by 88.79% to -$327.5 million in 2022, then skyrocketed by 68.72% to -$102.4 million in 2023, then grew by 13.74% to -$88.4 million in 2024, then plummeted by 92.63% to -$170.2 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$170.2 million, -$177.2 million, and -$338.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.